Published: 30 October 2021
Author(s): Maurizio Averna, Alberico L. Catapano
Issue: January 2022
Section: Review Article

The recent ESC/EAS 2019 Guidelines for the management of dyslipidaemias are centred on the causal role of low density lipoprotein (LDL), or more generally apolipoprotein B (apoB)-containing lipoproteins, in atherosclerosis as an essential principle. Despite updated goals and recommendations, that have further highlighted the importance of a powerful reduction in LDL-C levels to reduce the individual CV risk, some challenges remain to be addressed in view of future guideline elaboration. In this review, we will summarize the new evidence from clinical trials since 2019 guideline release and discuss the possible challenges for the future.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.